Cerus (NASDAQ:CERS) Stock, Quote.Headers.trade-ideas

Cerus

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CERS

CHGG

HPAI

MUFG

SMFG

ZoomInfo Reports Weak Results, Joins Chegg And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

wall-street-ai17

Intraday Update

BFAM

DASH

EZPW

FTEL

GDDY

ICFI

MELI

TNDM

WLDN

MercadoLibre Posts Upbeat Results, Joins Integral Ad Science, Willdan Group, Fresh Del Monte Produce And Other Big Stocks Moving Higher On Friday

movers image

AMAT

AMKR

ASML

CLNE

FIVE

GPCR

HYLN

SAVA

SAVE

ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Cerus Corp

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Tuesday.
Shares of ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) shares declined 15.2% to $8.31 in pre-market trading after the company reported worse-than-expected financial results for the second quarter and <a href="https://www.benzinga.com/news/24/08/40173882/zoominfo-technologies-q2-earnings-revenue-miss-eps-miss-soft-guidance-cfo-transition-and-more">announced a management transition</a>.
The company announced that CFO Cameron Hyzer will step down from his role. Hyzer will remain in an advisory capacity until Oct. 7 to help facilitate a smooth transition. Graham O&#8217;Brien has been named interim CFO, effective Sept. 6.
ZoomInfo Technologies shares dipped 15.2% to $8.31 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Chegg Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares declined 18.7% to $2.38 in pre-market trading following second-quarter results.</li>
<li>Helport AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPAI#NASDAQ">HPAI</a>) shares fell 15.2% to $7.15 in pre-market trading after declining 24% on Monday.</li>
<li>Sumitomo Mitsui Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMFG#NYSE">SMFG</a>) fell 10.5% to $10.80 in pre-market trading after declining around 4% on Monday.</li>
<li>Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) shares declined 8% to $26.83 in pre-market trading following weak quarterly sales.</li>
<li>Mizuho Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFG#NYSE">MFG</a>) fell 7% to $3.57 in pre-market trading after declining over 5% on Monday.</li>
<li>Mitsubishi UFJ Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>) shares declined 5.6% to $8.96 in pre-market trading.</li>
<li>Cerus Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) fell 4.5% to $2.12 in pre-market trading following a 5% decline on Monday.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) shares slipped 3.6% to $57.78. Sea will announce its second quarter results before the opening bell on Aug. 13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40178833/dow-records-worst-day-in-around-2-years-mag-7-stocks-lose-650b-in-market-capitalization-greed-index">Dow Records Worst Day In Around 2 Years, Mag 7 Stocks Lose $650B In Market Capitalization: Greed Index Moves To &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

ZoomInfo Reports Weak Results, Joins Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stocks were lower, with the Dow Jones index falling over 900 points on Friday.
Shares of MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) rose sharply during Friday's session after the company reported better-than-expected quarterly financial results.
Mercado Libre reported net revenue of $5.07 billion in the second quarter, up 42% year-over-year. The revenue beat a Street consensus estimate of $4.68 billion, according to data from Benzinga Pro.
The company reported a 36% year-over-year increase in total payment volume for the second quarter and a 20% year-over-year rise in gross merchandise volume. Earnings per share were $10.48 in the second quarter, beating a Street consensus estimate of $8.43.
MercadoLibre shares jumped 9.6% to $1,760.79 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) gained 26% to $24.50.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares surged 23.6% to $43.52 in pre-market trading following better-than-expected second-quarter earnings and strong guidance.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) gained 23% to $2.5200  after the company reported better-than-expected second-quarter EPS results and raised its FY24 product revenue guidance above estimates..</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) shares gained 14.9% to $11.38 after the company reported better-than-expected quarterly financial results and issued FY24 revenue guidance above estimates.</li>
<li>Willdan Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) climbed 10.1% to $36.52 after the company reported better-than-expected second-quarter financial results.</li>
<li>Fresh Del Monte Produce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) gained 8.6% to $26.73 following better-than-expected earnings.</li>
<li>ICF International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) rose 8.3% to $158.06 following upbeat quarterly results.</li>
<li>EZCORP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) jumped 8.2% to $11.35.</li>
<li>Standard BioTools Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NYSE">LAB</a>) gained 7.7% to $1.530.</li>
<li>Bright Horizons Family Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) gained 7.5% to $127.32 following strong quarterly results.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) rose 6.7% to $115.52 as the company posted upbeat earnings.</li>
<li>GoDaddy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) jumped 5.8% to $149.66 after the company reported better-than-expected second-quarter sales results..</li>
<li>The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) gained 4.3% to $139.94 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 adjusted EPS guidance above estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40131885/dow-dips-over-400-points-apple-posts-upbeat-earnings">Dow Dips Over 400 Points; Apple Posts Upbeat Earnings</a></li>
</ul>

WIIM

Cerus shares are trading higher after the company reported better-than-expected Q2 EPS results and raised its FY24 product revenue guidance above estimates.

Guidance

Cerus Reiterates FY24 IFC Revenue Guidance Of $8M - $10M

Cerus Increases FY24 Product Revenue Guidance Range From $172M-$175M To $175M-$178M

Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $45.079 million which missed the analyst consensus estimate of $46.627 million by 3.32 percent. This is a 16.02 percent increase over sales of $38.853 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Cerus Q2 2024 GAAP EPS $(0.03) Beats $(0.04) Estimate, Sales $45.079M Miss $46.627M Estimate

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 300 points on Wednesday.
Shares of ASML Holding N.V.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) fell in today's pre-market trading following the release of <a href="https://www.benzinga.com/news/earnings/24/07/39808860/asml-beats-q2-earnings-expectations-with-strong-china-sales-ai-chip-demand">second-quarter results.</a>
The Dutch company reported a second-quarter net income of 1.6 billion euros ($1.75 billion) on revenues of 6.2 billion euros ($6.77 billion), surpassing analysts' expectations of 1.41 billion euros on revenue of 6.04 billion euros, Reuters reported on Wednesday. The new bookings for the quarter stood at 5.6 billion euros ($6.11 billion), a significant increase from the 3.6 billion euros in the first quarter of 2024.
ASML shares dipped 6.8% to $995.90 in the pre-market trading session.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) shares dipped 26.5% to $9.95 in pre-market trading after announcing changes in executive leadership. The company named Rick Barry as Executive Chairman and Principal Executive Office and said Remi Barbier resigned as President, CEO, and Board Member.</li>
<li>Logistic Properties of the Americas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares tumbled 15.2% to $22.04 in pre-market trading after jumping 69% on Tuesday.</li>
<li>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) shares dipped 14.7% to $87.00 in pre-market trading after the company announced a CEO transition. Additionally, comparable sales decreased in the 10-week period ended July 13.</li>
<li>Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) fell 11% to $39.75 in pre-market trading.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined 8.4% to $2.19 in pre-market trading. On July 2, Cerus announced the appointment of Dean Gregory to its Board of Directors.</li>
<li>Clean Energy Fuels Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) shares fell 8% to $2.53 in pre-market trading. Clean Energy Fuels is expected to release financial results for the second quarter on Aug. 7, after the closing bell.</li>
<li>Hyliion Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) shares declined 6.2% to $2.26 in pre-market trading.</li>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) shares declined 5.7% to $2.98 in pre-market trading as the company issued soft second-quarter preliminary revenue estimates. The company estimated total revenue for the second quarter of 2024 to be approximately $1.28 billion, lower than previously expected primarily due to lower-than-expected non-ticket revenue.</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) shares fell 5.2% to $42.34 in pre-market trading. Amkor Technology is expected to issue its financial results for the second quarter after the closing bell on Monday, July 29.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) shares fell 3.9% to $236.30 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39809435/asml-united-airlines-and-3-other-stocks-to-watch-heading-into-wednesday">ASML, United Airlines And 3 Other Stocks To Watch Heading Into Wednesday</a></li>
</ul>

ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose sharply in today's pre-market trading after the company announced a strategic <a href="https://www.benzinga.com/news/24/07/39804803/bloom-energy-stock-booms-on-ai-data-center-deal-what-you-need-to-know">partnership with CoreWeave</a>.
Bloom Energy said it entered into a partnership to deploy its proprietary fuel cells to generate on-site power for CoreWeave at a high-performance data center in Illinois.
Bloom Energy shares jumped 12.1% to $16.90 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Shimmick Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) gained 53% to $3.09 in pre-market trading after the company received a $27.6 million subcontract for the Sunol Valley Water Treatment Plant Ozonation Project.</li>
<li>Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares rose 39.3% to $0.46 in pre-market trading after surging around 10% on Tuesday. Aptevo Therapeutics recently announced closing of $2.75 million offering.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares rose 26.1% to $3.58 in pre-market trading after declining around 14% on Tuesday.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) rose 16.1% to $0.2916 in pre-market trading. Conduit Pharmaceuticals shares gained around 5% on Tuesday after the company announced it received patent approval for its lead asset targeting autoimmune diseases..</li>
<li>Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) shares gained 15.5% to $10.31 in pre-market trading. Adverum Biotechnologies revealed 26-week interim analysis results of Ixo-vec from LUNA Phase 2 trial at 2024 ASRS Annual Meeting.</li>
<li>GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) gained 13.9% to $57.71 in pre-market trading after Reuters reported that the company is exploring a sale.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) shares climbed 12.6% to $1.77 in pre-market trading.</li>
<li>Immersion Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMR#NASDAQ">IMMR</a>) shares surged 12.4% to $13.69 in pre-market trading after gaining over 5% on Tuesday.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares gained 7.7% to $0.21 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cineverse Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNVS#NASDAQ">CNVS</a>) shares fell 15.6% to $0.75 in pre-market trading.</li>
<li>Logistic Properties of the Americas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares fell 15.2% to $22.04 in pre-market trading after jumping 69% on Tuesday.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 15.2% to $1.28 in pre-market trading after jumping 41% on Tuesday.</li>
<li>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) shares declined 14.7% to $87.00 in pre-market trading after the company announced a CEO transition. Additionally, comparable sales decreased in the 10-week period ended July 13.</li>
<li>Safe and Green Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGD#NASDAQ">SGD</a>) shares dipped 11% to $0.3642 in pre-market trading.</li>
<li>Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 9.2% to $2.17 in pre-market trading. Silo Pharma shares jumped 123% on Tuesday after the company obtained an exclusive global license to develop, manufacture, and commercialize its Alzheimer&#8217;s drug.</li>
<li>Eightco Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTO#NASDAQ">OCTO</a>) shares fell 8.7% to $0.48 in pre-market trading. Eightco Holdings recently said first-quarter revenue fell to $9.6 million from $15.9 million in the year-ago period.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) fell 8.4% to $2.19 in pre-market trading. On July 2, Cerus announced the appointment of Dean Gregory to its Board of Directors.</li>
<li>Siebert Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEB#NASDAQ">SIEB</a>) fell 6.8% to $1.77 in pre-market trading after gaining over 9% on Tuesday.</li>
<li>ASML Holding N.V.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shares declined 6.8% to $995.90 in pre-market trading. ASML reported better-than-expected second-quarter earnings, driven by robust sales in China and a surge in new bookings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39792248/jim-cramer-says-if-you-sell-this-chinese-ev-stock-now-some-clown-will-be-real-posit">Jim Cramer Says If You Sell This Chinese EV Stock Now, &#8216;Some Clown&#8217; Will Be &#8216;Real Positive About It,&#8217; Wait Until &#8216;All That Stuff Happens&#8217;</a></li>
</ul>

ADVM

APVO

ASST

CERO

CNVS

GTLB

IMMR

MLGO

OCTO

SHIM

SIEB

SILO

VRPX

Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

The Dow Jones index closed lower by over 80 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Earth Science Tech</h3>
<ul>
<li>The Trade: Earth Science Tech, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ETST#OTC">ETST</a>) Director Yovan Arturo Sanchez <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,500 shares</a> at an average price of $0.10. To acquire these shares, it cost around $1,050.</li>
<li>What's Happening: On Jan. 29, Earth Science Tech announced a $5 million common stock repurchase program.</li>
<li>What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company. Currently, the company is focused on emerging prospects in the health and wellness industry.</li>
</ul>
<h3 class="wp-block-heading">Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) Director R Janet Whitmore <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,300 shares at</a> an average price of $1.40. To acquire these shares, it cost around $7,420.</li>
<li>What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
<h3 class="wp-block-heading">Cerus</h3>
<ul>
<li>The Trade: Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) Director Jami K Nachtsheim <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,000 shares</a> at an average price of $1.79. The insider spent around $3,578 to buy those shares.</li>
<li>What's Happening: On May 2, Cerus said product revenue during the first quarter of 2024 was $38.4 million, up from $31.0 million in the year-ago period.</li>
<li>What Cerus Does: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety.</li>
</ul>
<h3 class="wp-block-heading">Zomedica</h3>
<ul>
<li>The Trade: Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) CEO Larry C Heaton II <a href="https://www.benzinga.com/quote/RVP/analyst-ratings">acquired a total of 100,000 shares</a> at an average price of $0.14. The insider spent around $14,200 to buy those shares.</li>
<li>What's Happening: On May 9, Zomedica reported a year-over-year decease in first-quarter GAAP EPS results and issued worse-than-expected quarterly sales results.</li>
<li>What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.</li>
</ul>
Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38807221/home-depot-paysafe-and-3-stocks-to-watch-heading-into-tuesday">Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday</a>

Long Ideas

Penny Stocks

Insider Trades

ETST

NANX

Zomedica And 3 Other Stocks Under $3 Insiders Are Buying

The Dow Jones index closed higher by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">ESS Tech</h3>
<ul>
<li>The Trade: ESS Tech, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) Director Harry Quarls <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 42,690 shares</a> at an average price of $0.84. To acquire these shares, it cost around $35,817.</li>
<li>What's Happening: On May 7, ESS Tech posted a narrower-than-expected quarterly loss.</li>
<li>What ESS Tech Does: ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology.</li>
</ul>
<h3 class="wp-block-heading">Cerus</h3>
<ul>
<li>The Trade: Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) Director Daniel N Swisher Jr <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,500 shares at </a>an average price of $1.88. To acquire these shares, it cost around $4,689.</li>
<li>What's Happening: On May 2, Cerus said product revenue during the first quarter of 2024 was $38.4 million, up from $31.0 million in the year-ago period.</li>
<li>What Cerus Does: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety.</li>
</ul>
<h3 class="wp-block-heading">Sabre</h3>
<ul>
<li>The Trade: Sabre Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) CEO and President Kurt Joseph Ekert <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 65,000 shares</a> at an average price of $2.57. The insider spent around $167,050 to buy those shares. The company's EVP and Chief Legal Officer also bought 20,000 shares.</li>
<li>What's Happening: On May 2, Sabre reported better-than-expected first-quarter results and updated FY24 revenue outlook.</li>
<li>What Sabre Does: Sabre holds the number-two air booking volume share in the global distribution system industry.</li>
</ul>
Read More: Enbridge, <a href="https://www.benzinga.com/news/earnings/24/05/38753455/enbridge-funko-and-3-stocks-to-watch-heading-into-friday">Funko And 3 Stocks To Watch Heading Into Friday</a>

SABR

ESS Tech And 2 Other Stocks Under $5 Insiders Are Buying

Cantor Fitzgerald analyst Ross Osborn maintains Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) with a Overweight and raises the price target from $3 to $4.

Price Target

Analyst Ratings

Cantor Fitzgerald Maintains Overweight on Cerus, Raises Price Target to $4

Craig-Hallum initiates coverage on Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) with a Buy rating and announces Price Target of $5.

Initiation

Craig-Hallum Initiates Coverage On Cerus with Buy Rating, Announces Price Target of $5

U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday.
Shares of Perion Network Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/peri#NASDAQ">PERI</a>) fell sharply in today&rsquo;s pre-market trading after the company <a href="https://www.benzinga.com/quote/PERI">slashed FY24 revenue guidance.</a>
Perion Network said it sees first-quarter revenue of $157 million, versus market estimates of $175.53 million. The company said it now expects FY24 revenue of $590 million to $610 million, versus prior outlook of $860 million to $880 million.
Perion Network shares dipped 37.6% to $13.17 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>BRC Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brcc#NYSE">BRCC</a>) shares fell 7.8% to $4.38 in pre-market trading after gaining over 5% on Friday.</li>
<li>Range Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rrc#NYSE">RRC</a>) shares declined 7.3% to $32.46 in pre-market trading. Range Resources is expected to release its first quarter 2024 financial results on April 23 after the closing bell.</li>
<li>Cerus Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cers#NASDAQ">CERS</a>) fell 4.9% to $1.78 in pre-market trading. On March 26, Cerus announced the FDA approval of extended shelf life for INTERCEPT platelet processing sets, doubling previous shelf life.</li>
<li>Oil States International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ois#NYSE">OIS</a>) shares declined 4.5% to $6.15 in pre-market trading after gaining around 4% on Friday.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tvgn#NASDAQ">TVGN</a>) fell 3.8% to $2.81 in pre-market trading after dipping 14% on Friday.</li>
<li>Rentokil Initial plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rto#NYSE">RTO</a>) climbed 3.8% to $29.04 in pre-market trading.</li>
<li>Baidu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bidu#NASDAQ">BIDU</a>) fell 3% to $103.30 in pre-market trading.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38136222/investor-sentiment-improves-following-jobs-data-dow-jumps-over-300-points"> Investor Sentiment Improves Following Jobs Data, Dow Jumps Over 300 Points</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Small Cap

BIDU

BRCC

PERI

TVGN

Perion Network Cuts Sales Outlook, Joins Range Resources And Other Big Stocks Moving Lower In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 11.96% to $1.31. The market value of their outstanding shares is at $2.1 million. </li>
<li>Etao International Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETAO#NASDAQ">ETAO</a>) stock moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $13.8 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares rose 7.35% to $2.39. The market value of their outstanding shares is at $1.7 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) stock rose 6.99% to $12.62. The market value of their outstanding shares is at $294.9 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock increased by 6.79% to $1.1. The market value of their outstanding shares is at $248.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock declined by 10.3% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $81.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares decreased by 4.9% to $0.02. The market value of their outstanding shares is at $1.1 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock fell 4.82% to $1.78. The market value of their outstanding shares is at $322.6 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares declined by 4.7% to $1.42. The company's market cap stands at $69.6 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 4.63% to $2.06. The market value of their outstanding shares is at $140.4 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) stock declined by 4.33% to $12.03. The market value of their outstanding shares is at $623.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ATNF

ELTX

ETAO

GOSS

LGVN

MNOV

SINT

STOK

12 Health Care Stocks Moving In Friday's After-Market Session

Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories are now eligible for this six-month extension. This shelf-life extension applies to all sizes of INTERCEPT Platelet Processing Sets currently available in the U.S.
"We are pleased with this successful and timely outcome to our regulatory filing with the FDA to re-establish a longer shelf life for INTERCEPT Platelet Processing Sets in the U.S.," said Vivek Jayaraman, Cerus' chief operating officer. "We expect that this extension will provide relief to our customers' and our supply chains and will give customers the flexibility to balance inventory levels with current and future demand while reducing product expiration risk."
The Company is continuing to generate additional data to pursue potential shelf life extension from the FDA beyond 12 months for the INTERCEPT Platelet Processing Sets.

Biotech

General

Cerus Corporation Announces FDA Approval Of Extended Shelf Life For INTERCEPT Platelet Processing Sets, Doubling Previous Shelf Life

On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) amidst Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) prices recovering.
The Block Inc Trade
The sale, worth $3.5 million, was executed through Ark's flagship ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) with a total of 42,608 shares sold. The value of the trade, calculated from the latest closing price of $81.46. Notably, at the time of writing, Bitcoin traded nearly 6.6% higher at $67,330.71.
Ark has sold Block shares in every trading session of the current week. On Monday, Ark sold Block <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37811799/cathie-wood-led-ark-invest-sheds-shares-of-jack-dorseys-block-and-coinbase-as-bitcoin-ethe">shares worth $8.95 million</a> and on Tuesday, the firm <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37838566/cathie-woods-ark-invest-isnt-done-selling-shares-of-jack-dorsey-led-block-yet-sheds-7-5m-w">sold $7.5 million worth</a>. For the week, including Wednesday&#8217;s sale, the total stands at $19.95 million.
Notably, Wood came to the defense of Block when the short seller Hindenburg issued an adverse report against the company.
Other Key Trades:
Ark Invest bought shares of Cerus Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>). The firm also bought shares of Personalis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>).
Ark also purchased shares of Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) through its ARKK fund. Shares of Twilio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) were sold from both the ARKK and ARKW portfolios.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37766119/whopping-33-8-million-shifted-to-robinhood-and-people-suspect-this-person-could-be-behind-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Whopping $33.8 Million Worth Of Dogecoin Shifted To Robinhood — And People Suspect This Person Could Be Behind It</a>
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ETFs

$BTC

ARKK

ARKW

MRNA

PSNL

TWLO

Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery

Tuesday,&nbsp;Cerus Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) announced topline results for the ReCePI Phase 3 trial of pathogen-reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/b37818869/cerus-corporation-announces-positive-topline-results-for-the-phase-3-clinical-trial-of-the-interce" rel="noreferrer noopener">cardiac surgery patients</a>.&nbsp;
The INTERCEPT Blood System for Red Blood Cells is designed to inactivate blood-borne pathogens and donor leukocytes in RBCs intended for transfusion.
The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs.&nbsp;
AKI is a sensitive transfusion efficacy indicator of RBC tissue oxygen delivery.&nbsp;
In transfused subjects, by modified intent to treat (mITT pre-specified primary endpoint population) the incidence of AKI was 29.3% (46/157) for INTERCEPT RBC recipients compared to 28.0% (45/161) for conventional RBC recipients, demonstrating non-inferiority of INTERCEPT RBCs compared to conventional RBCs with an upper limit of the 95% confidence interval of 10.4% compared with a non-inferiority margin of 14.0% (p = 0.001).
The safety endpoint of the proportion of patients with any related treatment-emergent adverse events within 28 days of last transfusion was not significantly different for INTERCEPT RBCs (2.5%) compared to conventional RBCs (0.6%) (p = 0.130).&nbsp;
&#8220;We continue to look forward to completing the RedeS clinical trial, Cerus&#8217; ongoing pivotal Phase 3 clinical trial for INTERCEPT RBCs enrolling a broader patient population requiring RBC transfusion for acute and chronic anemia,&#8221; stated Richard Benjamin, Cerus&#8217; chief medical officer.&nbsp;
Cerus anticipates initiating a modular PMA application to the FDA in the second half of 2025, with the final PMA module submission planned for the second half of 2026 upon the anticipated completion of the RedeS clinical trial.&nbsp;
Price Action: CERS shares are up 3.23% at $1.91 on the last check Tuesday.
Photo by Narupon Promvichai from Pixabay

Health Care

Why Blood Components-Focused Cerus Stock Is Rising Tuesday

Cerus Corporation shares are trading higher after the company announced its ReCePI Phase 3 trial of INTERCEPT Blood System met its primary efficacy endpoint.

CERS: 64% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37819016">Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-Emergent Adverse Events Within 28 Days Of Last Transfusion Was Not Significantly Different For Intercept RBCs</a>
CRNX: 20% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37815626">Crinetics Pharmaceuticals shares are trading higher after the company&#39;s Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly achieved the primary and all secondary endpoints.</a>
HOTH: 60% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37819667">Hoth Therapeutics Says HT-ALZ Emerges As A Promising Novel Solution For Combating Neuroinflammation And Cognitive Deficits Associated With Alzheimer&#39;s Disease.</a>

CRNX

HOTH

Market-Moving News for March 19th

Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cerus (NASDAQ:<a href="https://investorplace.com/stock-quotes/cers-stock-quote/">CERS</a>) just reported results for the first quarter of 2024.<ul><li>Cerus reported earnings per share of -5 cents. This met the analyst estimate for EPS of -5 cents.</li><li>The company reported revenue of $38.37 million.</li><li>This was 6.75% worse than the analyst estimate for revenue of $41.14 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cers-stock-earnings-cerus-for-q1-of-2024/">CERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Joint (JYNT – Research Report) and Cerus (CERS – Research Report)...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Joint (JYNT) and Cerus (CERS)

TD Cowen analyst Josh Jennings has maintained their bullish stance on CERS stock, giving a Buy rating on May 3. Josh Jennings has given his Buy rat...

Cerus's Strong Q1 Growth and Promising INTERCEPT Technology Drive Buy Rating

Cerus (CERS) has provided an announcement. Stockholders of Cerus Corporation showed strong support during their 2024 Annual Meeting, endorsing the ...

Cerus Stockholders Endorse New Plans and Board Members

Cerus (CERS) has issued an update. Dean Gregory, previously President of Global Commercial Operations at Med Tech for Fresenius Kabi, has accepted ...

Dean Gregory Joins Cerus Board with Compensation Package

Cerus GAAP EPS of -$0.03 beats by $0.01, revenue of $50.5M beats by $7.99M

Cerus Corporation (CERS) Q2 2024 Earnings Call Transcript

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Cerus (CERS – Research Report), with a price target of $5.00. Jo...

Cerus Corporation: A Strong Buy on Robust Revenue Growth and Market Expansion

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Takeda Pharmaceutical Co (TKPHF – Research Report), ...

Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Co (OtherTKPHF), Cerus (CERS) and Ultragenyx Pharmaceutical (RARE)

JYNT

RARE

TKPHF

Press Releases

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024

Cerus Corporation Announces First Quarter 2024 Financial Results

Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

Cerus Corporation Celebrates World Blood Donor Day 2024

Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion

Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024

Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Cerus

Cerus (CERS) Forecast

Cerus (NASDAQ:CERS) Stock, Quote.Headers.trade-ideas